https://scholars.lib.ntu.edu.tw/handle/123456789/531091
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | Chiu P.-C. | en_US |
dc.contributor.author | Hsieh P.-Y. | en_US |
dc.contributor.author | Kang J.-W. | en_US |
dc.contributor.author | Chang P.-H. | en_US |
dc.contributor.author | LI-JIUAN SHEN | en_US |
dc.creator | Chiu P.-C.;Hsieh P.-Y.;Kang J.-W.;Chang P.-H.;Li-Jiuan Shen | - |
dc.date.accessioned | 2020-12-24T03:00:36Z | - |
dc.date.available | 2020-12-24T03:00:36Z | - |
dc.date.issued | 2020 | - |
dc.identifier.issn | 1061186X | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/531091 | - |
dc.description.abstract | The targeted delivery of therapeutic agents is a promising approach to enhance the efficacy and reduce the toxicity of cancer treatments. Understanding the intracellular endocytic mechanisms of a cell penetrating peptide (CPP) in an acidic environment is important for targeted delivery of macromolecules to tumours. In this study, we constructed a pH-sensitive CPP-based delivery system for the intracellular delivery of macromolecules. A pH-sensitive CPP, HBHAc, was fused with a model protein, enhanced green fluorescent protein (EGFP), through recombinant DNA technology. We found that is essential that negatively charged proteoglycans on the cell surface interact with HBHAc-EGFP prior to the cellular uptake of HBHAc-EGFP. The uptake was significantly restricted at 4 °C under pH conditions of both 6.5 and 7.5. The increased positive charge of HBHAc-EGFP under the acidic condition leads to a pH-dependent cellular uptake, and we observed that the internalisation of HBHAc-EGFP was significantly higher at pH 6.5 than at pH 7.5 (p <.05). Thus, with pH-sensitive activity, HBHAc is expected to improve tumour-targeted intracellular protein delivery. Moreover, our findings provide a new insight that the endocytic pathway may change under different pH conditions and suggest that this unique phenomenon benefits pH-sensitive drug delivery for tumour therapy. ? 2019, ? 2019 Informa UK Limited, trading as Taylor & Francis Group. | - |
dc.relation.ispartof | Journal of Drug Targeting | - |
dc.subject | Cell-penetrating peptide (CPP); HBHAc; intracellular protein delivery; mechanism; pH sensitive | - |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | cell penetrating peptide; cell protein; enhanced green fluorescent protein; fusion protein; heparin binding hemagglutinin adhesion protein; proteoglycan; recombinant protein; unclassified drug; cell penetrating peptide; enhanced green fluorescent protein; green fluorescent protein; acidity; Article; cancer therapy; cell surface; cell viability; controlled study; drug delivery system; endocytosis; human; human cell; internalization; macromolecule; pH; priority journal; protein modification; recombinant DNA technology; cell membrane; cytoplasm; drug delivery system; drug effect; Hep-G2 cell line; metabolism; neoplasm; pH; procedures; signal transduction; tumor cell line; Cell Line, Tumor; Cell Membrane; Cell-Penetrating Peptides; Cytoplasm; Drug Delivery Systems; Endocytosis; Green Fluorescent Proteins; Hep G2 Cells; Humans; Hydrogen-Ion Concentration; Neoplasms; Signal Transduction | - |
dc.title | Study of the intracellular delivery mechanism of a pH-sensitive peptide modified with enhanced green fluorescent protein | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.1080/1061186X.2019.1669041 | - |
dc.identifier.pmid | 31524004 | - |
dc.identifier.scopus | 2-s2.0-85076556011 | - |
dc.relation.pages | 408-418 | - |
dc.relation.journalvolume | 28 | - |
dc.relation.journalissue | 4 | - |
item.cerifentitytype | Publications | - |
item.fulltext | no fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.openairetype | journal article | - |
item.grantfulltext | none | - |
crisitem.author.dept | Clinical Pharmacy | - |
crisitem.author.dept | Office of International Affairs | - |
crisitem.author.orcid | 0000-0002-2854-3205 | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | Administrative Unit | - |
顯示於: | 臨床藥學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。